Big Pharma behaving badly (page 2)

Abbott
With: Twenty-three states
When: Jan. 7, 2010
Scoop: In a case involving 23 different states, Abbott Laboratories and its partner, Fournier Industrie et Sante, were ordered to pay $22.5 million for blocking the states from obtaining a cheaper alternative for its cholesterol drug, TriCor.

Eli Lilly
With: Connecticut
When: Sept. 29, 2009
Scoop: Thirteen states total had filed suit against Eli Lilly for Zyprexa marketing issues, but the company was ordered to pay $25 million to Connecticut in this ruling.

Eli Lilly
With: West Virginia Attorney General
When: August 21, 2009
Scoop: In another Zyprexa case, West Virginia Attorney General Darrell McGraw levied $2 billion in fines against Eli Lilly. As the motion put it, "At $5,000 per violation, therefore, the State is attempting to fine Lilly approximately $2 billion for use of a product label that was approved by the FDA." In the end, the company agreed to $22.5 million in fines.

Merck
With: 35 states' attorney offices
When: July 15, 2009
Scoop: Merck escaped relatively unscathed from 35 state investigations against the Enhance study of Vytorin, only paying $5.4 million without admitting fault in the cases.

Sanofi-aventis
With: Department of Justice
When: May 28, 2009
Scoop: In an agreement with the federal government, Sanofi paid $95.5 million total, doled out to the feds, state Medicaid agencies and other public health service agencies, all for its subsidiary Aventis' nasal spray price inflation between 1995 and 2000.

GlaxoSmithKline
With: U.S. Attorney's office in Colorado
When: Jan. 29, 2009
Scoop: After seven years of off-label promotion on nine of its best-selling drugs, GSK was ordered to pay $400 million to the U.S. Attorney's office in Colorado.

Pfizer
With: Department of Justice
When: Jan. 26, 2009
Scoop: Right after acquiring Wyeth, Pfizer dropped a bombshell in its fourth quarter earnings report; the company was charged $2.3 billion, the largest fine levied on our list, for off-label promotions of its COX-2 drugs. That settlement lowered the company's 2008 net income by 90 percent.

Eli Lilly
With: Department of Justice
When: Jan. 15, 2009
Scoop: In the first Zyprexa settlement (and one of three on our list), the Department of Justice levied $1.4 billion in fines against Eli Lilly. Also, as part of the settlement, the company pled guilty to a misdemeanor: violating the Food, Drug and Cosmetic Act.

Big Pharma behaving badly (page 2)
Read more on

Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.